Low Molecular Weight Heparins for Thromboprophylaxis during Induction Chemotherapy in Patients with Multiple Myeloma
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F11%3A7245" target="_blank" >RIV/00064203:_____/11:7245 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11130/11:7245 RIV/00216208:11150/11:10105307 RIV/65269705:_____/11:#0001403 RIV/00179906:_____/11:10105307 RIV/00843989:_____/11:00103144
Výsledek na webu
<a href="http://www.medvik.cz/link/bmc11033854" target="_blank" >http://www.medvik.cz/link/bmc11033854</a>
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Low Molecular Weight Heparins for Thromboprophylaxis during Induction Chemotherapy in Patients with Multiple Myeloma
Popis výsledku v původním jazyce
Backgrounds: Patients with multiple myeloma have a high risk of venous thromboembolism (VTE), especially during the induction chemotherapy. The aim of our observational study was to determine the impact of prophylaxis with low molecular weight heparin (LMWH) on the incidence of thromboembolic complications. Patients and Methods: We analyzed the incidence of thromboembolic events in 258 patients treated with induction chemotherapy containing vincristin, doxorubicin or idarubicin, and dexamethasone, followed by stimulation chemotherapy with cyclophosphamide and G-CSF, and high-dose chemotherapy with melphalan. Two groups of these patients were compared based on the practice of thromboprophylaxis. Patients in the first group (Control, n = 140) were eithernot treated or treated with a short duration of anticoagulation therapy while the patients in the second group (Prophylactic, n = 118) underwent standard prophylaxis with LMWH throughout the entire period of induction chemotherapy. A tot
Název v anglickém jazyce
Low Molecular Weight Heparins for Thromboprophylaxis during Induction Chemotherapy in Patients with Multiple Myeloma
Popis výsledku anglicky
Backgrounds: Patients with multiple myeloma have a high risk of venous thromboembolism (VTE), especially during the induction chemotherapy. The aim of our observational study was to determine the impact of prophylaxis with low molecular weight heparin (LMWH) on the incidence of thromboembolic complications. Patients and Methods: We analyzed the incidence of thromboembolic events in 258 patients treated with induction chemotherapy containing vincristin, doxorubicin or idarubicin, and dexamethasone, followed by stimulation chemotherapy with cyclophosphamide and G-CSF, and high-dose chemotherapy with melphalan. Two groups of these patients were compared based on the practice of thromboprophylaxis. Patients in the first group (Control, n = 140) were eithernot treated or treated with a short duration of anticoagulation therapy while the patients in the second group (Prophylactic, n = 118) underwent standard prophylaxis with LMWH throughout the entire period of induction chemotherapy. A tot
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2011
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Klinická onkologie
ISSN
0862-495X
e-ISSN
—
Svazek periodika
24
Číslo periodika v rámci svazku
4
Stát vydavatele periodika
CZ - Česká republika
Počet stran výsledku
6
Strana od-do
281-286
Kód UT WoS článku
—
EID výsledku v databázi Scopus
—